Becton, Dickinson and Company $BDX Shares Sold by Teacher Retirement System of Texas

Teacher Retirement System of Texas lessened its stake in Becton, Dickinson and Company (NYSE:BDX) by 9.1% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 42,097 shares of the medical instruments supplier’s stock after selling 4,206 shares during the quarter. Teacher Retirement System of Texas’ holdings in Becton, Dickinson and Company were worth $7,879,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. SOA Wealth Advisors LLC. boosted its holdings in shares of Becton, Dickinson and Company by 256.8% in the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 95 shares in the last quarter. Bell Investment Advisors Inc lifted its position in Becton, Dickinson and Company by 474.1% in the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 128 shares during the period. Grey Fox Wealth Advisors LLC acquired a new stake in Becton, Dickinson and Company in the third quarter worth approximately $32,000. Bank of Jackson Hole Trust boosted its stake in Becton, Dickinson and Company by 85.6% during the 2nd quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 95 shares in the last quarter. Finally, CVA Family Office LLC raised its stake in shares of Becton, Dickinson and Company by 79.5% in the 2nd quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock worth $38,000 after buying an additional 97 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Morgan Stanley raised their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Stifel Nicolaus upped their price target on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Bank of America lifted their price objective on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research note on Monday, January 5th. Piper Sandler cut their target price on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, November 7th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $207.64.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, Director Bertram L. Scott sold 217 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the sale, the director directly owned 35,816 shares of the company’s stock, valued at $6,324,389.28. This represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 2,605 shares of company stock worth $524,643 over the last three months. 0.40% of the stock is owned by insiders.

Becton, Dickinson and Company Stock Down 2.0%

BDX stock opened at $201.84 on Monday. Becton, Dickinson and Company has a 52-week low of $162.29 and a 52-week high of $251.99. The company’s 50 day simple moving average is $197.40 and its 200-day simple moving average is $190.53. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64. The firm has a market capitalization of $57.51 billion, a P/E ratio of 34.62, a P/E/G ratio of 2.23 and a beta of 0.23.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The firm had revenue of $5.89 billion during the quarter, compared to analyst estimates of $5.91 billion. During the same quarter last year, the business posted $3.81 EPS. The company’s revenue was up 8.3% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th were issued a dividend of $1.05 per share. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date was Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio is presently 72.04%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.